What is Leerink Partnrs' Estimate for BBIO FY2027 Earnings?

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Leerink Partnrs dropped their FY2027 earnings estimates for BridgeBio Pharma in a research note issued to investors on Sunday, November 24th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of $1.30 per share for the year, down from their prior estimate of $1.31. The consensus estimate for BridgeBio Pharma's current full-year earnings is ($2.56) per share.

Other equities analysts also recently issued research reports about the company. Scotiabank raised their price target on BridgeBio Pharma from $45.00 to $48.00 and gave the stock a "sector outperform" rating in a research report on Monday. Cantor Fitzgerald reissued an "overweight" rating and issued a $70.00 target price on shares of BridgeBio Pharma in a research note on Monday, September 16th. Leerink Partners decreased their price target on shares of BridgeBio Pharma from $47.00 to $46.00 and set an "outperform" rating on the stock in a research note on Thursday, October 17th. Piper Sandler initiated coverage on shares of BridgeBio Pharma in a research report on Wednesday, September 4th. They issued an "overweight" rating and a $46.00 price objective for the company. Finally, Evercore ISI decreased their target price on shares of BridgeBio Pharma from $50.00 to $45.00 and set an "outperform" rating on the stock in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $48.43.

BridgeBio Pharma Stock Down 2.8 %

Shares of BBIO traded down $0.75 during mid-day trading on Tuesday, reaching $26.44. 4,317,097 shares of the company's stock were exchanged, compared to its average volume of 1,921,169. BridgeBio Pharma has a 52-week low of $21.62 and a 52-week high of $44.32. The company has a market cap of $5.00 billion, a price-to-earnings ratio of -10.97 and a beta of 1.09. The company has a 50-day simple moving average of $24.97 and a two-hundred day simple moving average of $26.21.

Insider Activity

In other news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the firm's stock in a transaction on Friday, September 13th. The shares were sold at an average price of $25.75, for a total value of $149,350,000.00. Following the transaction, the insider now owns 25,260,971 shares of the company's stock, valued at approximately $650,470,003.25. This trade represents a 18.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Brian C. Stephenson sold 4,156 shares of the company's stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total transaction of $93,135.96. Following the sale, the chief financial officer now directly owns 93,758 shares of the company's stock, valued at approximately $2,101,116.78. This trade represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,831,545 shares of company stock valued at $150,056,923 in the last three months. Corporate insiders own 24.66% of the company's stock.

Hedge Funds Weigh In On BridgeBio Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC lifted its position in shares of BridgeBio Pharma by 189.7% during the first quarter. Janus Henderson Group PLC now owns 3,312,706 shares of the company's stock worth $102,402,000 after purchasing an additional 2,169,143 shares in the last quarter. Ensign Peak Advisors Inc lifted its holdings in BridgeBio Pharma by 44.5% in the 2nd quarter. Ensign Peak Advisors Inc now owns 1,646,202 shares of the company's stock worth $41,698,000 after buying an additional 506,845 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in BridgeBio Pharma by 40.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,534,972 shares of the company's stock valued at $38,881,000 after buying an additional 442,248 shares during the last quarter. Emerald Advisers LLC boosted its position in BridgeBio Pharma by 65.6% in the 3rd quarter. Emerald Advisers LLC now owns 1,103,508 shares of the company's stock valued at $28,095,000 after buying an additional 437,164 shares during the last quarter. Finally, First Turn Management LLC acquired a new stake in shares of BridgeBio Pharma during the third quarter valued at about $10,178,000. 99.85% of the stock is owned by institutional investors and hedge funds.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.